NZ623294A - Stabilized alpha-galactosidase and uses thereof - Google Patents
Stabilized alpha-galactosidase and uses thereofInfo
- Publication number
- NZ623294A NZ623294A NZ623294A NZ62329411A NZ623294A NZ 623294 A NZ623294 A NZ 623294A NZ 623294 A NZ623294 A NZ 623294A NZ 62329411 A NZ62329411 A NZ 62329411A NZ 623294 A NZ623294 A NZ 623294A
- Authority
- NZ
- New Zealand
- Prior art keywords
- galactosidase
- stabilized alpha
- linking moiety
- native
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30948710P | 2010-03-02 | 2010-03-02 | |
| PCT/IL2010/000956 WO2011061736A1 (en) | 2009-11-17 | 2010-11-17 | Alkaline alpha galactosidase for the treatment of fabry disease |
| US201161434499P | 2011-01-20 | 2011-01-20 | |
| US201161434503P | 2011-01-20 | 2011-01-20 | |
| NZ602317A NZ602317A (en) | 2010-03-02 | 2011-03-02 | Stabilized alpha-galactosidase and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ623294A true NZ623294A (en) | 2015-10-30 |
Family
ID=44121635
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ623294A NZ623294A (en) | 2010-03-02 | 2011-03-02 | Stabilized alpha-galactosidase and uses thereof |
| NZ602317A NZ602317A (en) | 2010-03-02 | 2011-03-02 | Stabilized alpha-galactosidase and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602317A NZ602317A (en) | 2010-03-02 | 2011-03-02 | Stabilized alpha-galactosidase and uses thereof |
Country Status (23)
| Country | Link |
|---|---|
| EP (3) | EP2542675B1 (enExample) |
| JP (2) | JP5758920B2 (enExample) |
| KR (1) | KR101928403B1 (enExample) |
| CN (1) | CN102933707B (enExample) |
| AU (1) | AU2011222452B2 (enExample) |
| BR (1) | BR112012022029B1 (enExample) |
| CA (1) | CA2791461C (enExample) |
| DK (1) | DK2865751T3 (enExample) |
| ES (2) | ES2708843T3 (enExample) |
| FI (1) | FIC20230032I1 (enExample) |
| FR (1) | FR23C1041I2 (enExample) |
| HR (1) | HRP20200428T1 (enExample) |
| HU (2) | HUE030959T2 (enExample) |
| IL (2) | IL221741A (enExample) |
| IN (1) | IN2012MN02262A (enExample) |
| NL (1) | NL301249I2 (enExample) |
| NO (1) | NO2023041I1 (enExample) |
| NZ (2) | NZ623294A (enExample) |
| PL (1) | PL2865751T3 (enExample) |
| SG (2) | SG183558A1 (enExample) |
| SI (1) | SI2865751T1 (enExample) |
| WO (1) | WO2011107990A1 (enExample) |
| ZA (1) | ZA201206725B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| DK2865751T3 (en) * | 2010-03-02 | 2017-01-09 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
| EP2665814B1 (en) * | 2011-01-20 | 2017-05-17 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
| TWI793159B (zh) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | 重組醣蛋白及其用途 |
| CA2970638A1 (en) | 2014-12-22 | 2016-06-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| WO2016116966A1 (en) * | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
| AU2016232149B2 (en) | 2015-03-17 | 2021-09-23 | eleva GmbH | Glycosylated lysosomal proteins, method of production and uses |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| US12194079B2 (en) * | 2017-01-05 | 2025-01-14 | Protalix Ltd. | Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase |
| EP4321212A3 (en) * | 2017-06-07 | 2024-05-15 | Amano Enzyme Inc. | Lactase bulk powder and lactase preparation |
| MY207075A (en) | 2018-12-20 | 2025-01-28 | Codexis Inc | Human alpha-galactosidase variants |
| TW202146648A (zh) * | 2020-02-28 | 2021-12-16 | 美商克迪科思股份有限公司 | 人類α-半乳糖苷酶變異體 |
| JP7833461B2 (ja) | 2020-11-03 | 2026-03-19 | プロタリクス リミテッド | 修飾ウリカーゼ及びその使用 |
| CN112176026A (zh) * | 2020-11-06 | 2021-01-05 | 诺道中科(北京)生物科技有限公司 | 一种α-半乳糖苷酶活性的检测试剂盒 |
| MX2023005580A (es) * | 2020-11-13 | 2023-05-29 | Hanmi Pharmaceutical Co Ltd | Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de enfermedades renales provocadas por o acompa?adas de la enfermedad de fabry. |
| CN116254287B (zh) * | 2022-11-24 | 2024-06-04 | 西北农林科技大学 | 玉米ZmAGA3基因用于提高植物耐旱性的应用 |
| US12703857B2 (en) | 2023-02-02 | 2026-08-11 | Protalix Ltd. | Methods of treating diseases associated with elevated uric acid |
| CN118243646B (zh) * | 2024-04-24 | 2025-01-24 | 武汉简为医疗科技有限公司 | 一种乳糖不耐受检测试剂盒及其使用方法 |
| JP7745040B1 (ja) | 2024-06-21 | 2025-09-26 | デンカ株式会社 | 目的タンパク質の回収方法及び製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| US6329191B1 (en) * | 1993-08-30 | 2001-12-11 | Hawaii Biotechnology Group, Inc. | DNA encoding recombinant coffee bean alpha-galactosidase |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US20050032211A1 (en) * | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
| DK1009759T3 (da) * | 1997-09-05 | 2008-08-04 | Altus Pharmaceuticals Inc | Carbohydrat-tværbundne glycoproteinkrystaller |
| IL125423A (en) | 1998-07-20 | 2004-08-31 | Israel State | Alkaline alpha-galactosidase having broad substrate specificity |
| CA2369869C (en) | 1999-04-02 | 2008-06-10 | Ajinomoto Co., Inc. | Process for producing subunit peptide originating in polymer protein |
| DK1523548T3 (da) | 2002-05-15 | 2010-05-10 | Agricultural Res Org | Polynukleotidsekvenser, som koder for alkaliske alfa-galactosidaser, og fremgangsmåder til anvendelse heraf |
| US7951557B2 (en) * | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| JP5137814B2 (ja) * | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| JP4368925B2 (ja) * | 2005-11-18 | 2009-11-18 | 財団法人 東京都医学研究機構 | 基質特異性を変換した新規高機能酵素 |
| WO2008075957A1 (en) | 2006-12-21 | 2008-06-26 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of fabry disease |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EP1955712A1 (en) * | 2007-02-09 | 2008-08-13 | Scil proteins GmbH | Multimeric conjugate |
| US8742079B2 (en) | 2007-08-20 | 2014-06-03 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| DK2865751T3 (en) * | 2010-03-02 | 2017-01-09 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
-
2011
- 2011-03-02 DK DK14195875.1T patent/DK2865751T3/en active
- 2011-03-02 AU AU2011222452A patent/AU2011222452B2/en active Active
- 2011-03-02 PL PL14195875T patent/PL2865751T3/pl unknown
- 2011-03-02 EP EP11712340.6A patent/EP2542675B1/en active Active
- 2011-03-02 IN IN2262MUN2012 patent/IN2012MN02262A/en unknown
- 2011-03-02 NZ NZ623294A patent/NZ623294A/en unknown
- 2011-03-02 EP EP14195875.1A patent/EP2865751B1/en active Active
- 2011-03-02 WO PCT/IL2011/000209 patent/WO2011107990A1/en not_active Ceased
- 2011-03-02 ES ES16173953T patent/ES2708843T3/es active Active
- 2011-03-02 JP JP2012555542A patent/JP5758920B2/ja active Active
- 2011-03-02 CA CA2791461A patent/CA2791461C/en active Active
- 2011-03-02 ES ES14195875.1T patent/ES2606532T3/es active Active
- 2011-03-02 SG SG2012064580A patent/SG183558A1/en unknown
- 2011-03-02 EP EP16173953.7A patent/EP3088514B1/en active Active
- 2011-03-02 SG SG10201502609QA patent/SG10201502609QA/en unknown
- 2011-03-02 BR BR112012022029-2A patent/BR112012022029B1/pt active IP Right Grant
- 2011-03-02 SI SI201131048A patent/SI2865751T1/sl unknown
- 2011-03-02 NZ NZ602317A patent/NZ602317A/en unknown
- 2011-03-02 HU HUE14195875A patent/HUE030959T2/en unknown
- 2011-03-02 CN CN201180022145.6A patent/CN102933707B/zh active Active
- 2011-03-02 KR KR1020127025725A patent/KR101928403B1/ko active Active
-
2012
- 2012-09-02 IL IL221741A patent/IL221741A/en active IP Right Grant
- 2012-09-07 ZA ZA2012/06725A patent/ZA201206725B/en unknown
-
2014
- 2014-08-06 JP JP2014160449A patent/JP5871999B2/ja active Active
-
2017
- 2017-06-29 IL IL253249A patent/IL253249B/en active IP Right Grant
-
2020
- 2020-03-16 HR HRP20200428TT patent/HRP20200428T1/hr unknown
-
2023
- 2023-10-31 HU HUS2300038C patent/HUS2300038I1/hu unknown
- 2023-11-01 NL NL301249C patent/NL301249I2/nl unknown
- 2023-11-01 NO NO2023041C patent/NO2023041I1/no unknown
- 2023-11-02 FI FIC20230032C patent/FIC20230032I1/fi unknown
- 2023-11-02 FR FR23C1041C patent/FR23C1041I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602317A (en) | Stabilized alpha-galactosidase and uses thereof | |
| PH12014501924A1 (en) | Xten conjugate compositions and methods of making same | |
| MY168297A (en) | Cytotoxic Peptides and Antibody Drug Conjugates Thereof | |
| WO2008036929A3 (en) | Complex for transferring an anionic substance into a cell | |
| IL212184A (en) | Conditional expression vector of protein (s) acting as immunomodulator (s), engineered training cells, their pharmaceutical composition and their use in drug preparation | |
| MX2015005122A (es) | Conjugados de farmaco-proteina novedosos. | |
| ZA201206504B (en) | Immunogenic composition comprising s. pneumoniae polysaccharides conjugates to carrier proteins | |
| MX2013015168A (es) | Co-agonista del receptor de glucagon/glp-1. | |
| PH12013502671A1 (en) | Glucagon/glp-1 receptor co-agonists | |
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| NZ580132A (en) | Binding ligand linked drug delivery conjugates of tubulysins to vitamins | |
| NZ629204A (en) | Anti-vla1 (cd49a) antibody pharmaceutical compositions | |
| MX342675B (es) | Formulaciones estables para inyeccion parenteral de farmacos de peptido. | |
| IL221205A0 (en) | Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof | |
| GB201106743D0 (en) | Novel compounds | |
| MX2012000575A (es) | Conjugados de epsilon-polilisina y uso de los mismos. | |
| PH12012502159A1 (en) | Pharmaceutical compositions and methods of making same | |
| MX2012003951A (es) | Preparacion farmceutica que comprende hcg recombinante. | |
| WO2013067199A3 (en) | Subcutaneous delivery of polymer conjugates of therapeutic agents | |
| NZ612161A (en) | Radiolabled her2 binding peptides | |
| AU2016219650A1 (en) | Compositions and methods for extended therapy with aminopyridines | |
| NZ601043A (en) | Nutritive compositions and methods of using same | |
| IL209967A (en) | Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl | |
| MX2015002482A (es) | Composicion inmunogenica. | |
| MX2010003045A (es) | Composiciones de ciclosporina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 MAR 2018 BY DENNEMEYER + CO Effective date: 20160416 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2019 BY DENNEMEYER + CO Effective date: 20180221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2020 BY DENNEMEYER Effective date: 20190219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2021 BY DENNEMEYER + CO. Effective date: 20200219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2022 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20210223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2023 BY DENNEMEYER + CO Effective date: 20220222 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2024 BY DENNEMEYER + CO. Effective date: 20230220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2025 BY MS. MANDY LAUBACH Effective date: 20240220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2026 BY DENNEMEYER AND CO. SARL Effective date: 20250226 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2027 BY BIRGIT KNAACK Effective date: 20260227 |